Boston Scientific (BSX) Stock Price & Analysis
BSX Stock Chart & Stats
- Day’s Range
- MXN 785.00 - MXN 806.92
- 52-Week Range
- MXN 728.00 - MXN 2,083.00
- Previous Close
- MXN 789.45
- Volume
- 60
- Average Volume (3M)
- 2,577
- Market Cap
- MXN 1.14T
- Enterprise Value
- MXN 75.16B
- Total Cash (Recent Filing)
- MXN 539.00M
- Total Debt (Recent Filing)
- MXN 12.62B
- Price to Earnings (P/E)
- 17.7
- Beta
- -0.09
- Next Earnings
- Feb 03, 2027 (Est.)
- EPS Estimate
- 14.69
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Margin Expansion
Sustained revenue growth alongside expanding profitability indicates meaningful operating leverage and stronger earnings power. The improvement across gross, operating, and net margins can support reinvestment in innovation, commercial execution, and capacity while strengthening competitiveness over the next several quarters.
Strong Cash Generation
High absolute operating and free cash flow gives Boston Scientific internal funding for product development, acquisitions, debt service, and shareholder returns. Free cash flow has tracked earnings reasonably well, supporting the quality and durability of the company’s growth investment capacity.
Broad Product And Market Growth
Growth across multiple procedure-focused businesses reduces reliance on a single device category and demonstrates continued clinician adoption of Boston Scientific technologies. Expansion in neuromodulation and cardiovascular therapies also supports recurring demand from procedures and future cross-selling opportunities.
Bears Say
2027 Growth Challenge
The expected 2027 growth challenge signals that recent execution and market pressures may persist beyond one quarter. Pressure from EP, WATCHMAN, China pricing, comp issues, and a competitive launch could restrain organic expansion and delay the company’s return to a stronger growth trajectory.
Competitive And Pricing Pressure
Weakness in important franchises can erode market position and reduce the benefits of Boston Scientific’s broader portfolio. Ongoing China pricing pressure and competition in EP and WATCHMAN may compress revenue quality and margins, requiring successful launches and stronger commercial execution to recover.
Cash Conversion Below Earnings
Although absolute cash generation is strong, consistently incomplete conversion of reported earnings into operating cash warrants monitoring. A 0.70x TTM coverage ratio could limit internally generated flexibility if it persists, making disciplined working-capital management and execution increasingly important.
BSX FAQ
What was Boston Scientific’s price range in the past 12 months?
What is Boston Scientific’s market cap?
When is Boston Scientific’s upcoming earnings report date?
How were Boston Scientific’s earnings last quarter?
Is Boston Scientific overvalued?
Does Boston Scientific pay dividends?
What is Boston Scientific’s EPS estimate?
How many shares outstanding does Boston Scientific have?
What happened to Boston Scientific’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Boston Scientific?
What is the TipRanks Smart Score and how is it calculated?
Boston Scientific Stock Smart Score
Company Description
Boston Scientific
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
- Sector
- General
- Industry
- Medical - Devices
- CEO
- Michael F. Mahoney
- Employees
- 59,000
- Website
- www.bostonscientific.com
- Address
- 300 Boston Scientific Way, Marlborough, MA, 01752-1234, US
Boston Scientific (BSX) Earnings & Revenues
BSX Company Deck
BSX Earnings Call
Earnings Call SentimentNegative
The call was dominated by near-term execution setbacks, including the cyber incident, a below-guidance third quarter, fourth-quarter revenue declines, margin pressure, China pricing headwinds, WATCHMAN and EP weakness, and an expected challenge to grow revenue and adjusted EPS in 2027. The company highlighted resilient operations, strong performance in several businesses, restructuring savings, product approvals, and a substantial future pipeline, but these positives were outweighed by the current downcycle and multiple forecast and launch challenges.
View all MX:BSX earnings summariesBSX Net sales Breakdown
- 33.99% MedSurg
- 66.01% Cardiovascular
BSX Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 6 | 13 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 0 | 0 | 12 |
